Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 124

Sort by

Sort Order Select

Journal Articles

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Blood (2025) 146 (Supplement 1): 643.

https://doi.org/10.1182/blood-2025-643

Published: 2025

Journal Articles

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study

Blood (2025) 146 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2025-3340

Published: 2025

Journal Articles

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Blood (2025) 146 (Supplement 1): 77.

https://doi.org/10.1182/blood-2025-77

Published: 2025

Journal Articles

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia

Isabelle De Araujo, Mathilde Marlas, Marie-Laure Nicolau, Inès Vergnolle, Lucie Donaty, Isabelle Luquet, Alban Canali, Lucie Rigolot, Laetitia Largeaud, Eric Delabesse, Véronique De Mas, Leopoldine Lapierre, Sarah Bertoli, Christian Recher, Jean-Emmanuel Sarry, Francoise Huguet, Suzanne Tavitian, Francois Vergez

Blood (2025) 146 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2025-3787

Published: 2025

Journal Articles

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Franck Nicolini, Francoise Huguet, Aude Charbonnier, Martine Escoffre-Barbe, Gabrielle Roth-Guepin, Shanti Amé, Emilie Cayssials, Mathieu Meunier, Charlotte Doublet, Vincent Alcazer, Stéphane Morisset, Romaine Mayet, Gwenaëlle Garin, Gabriel Etienne, Ivan Sloma, Olivier Mansier, Stéphanie Dulucq

Blood (2025) 146 (Supplement 1): 3773.

https://doi.org/10.1182/blood-2025-3773

Published: 2025

Journal Articles

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Blood (2025) 146 (Supplement 1): 5117.

https://doi.org/10.1182/blood-2025-5117

Published: 2025

Journal Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

Blood (2025) 146 (Supplement 1): 5567.

https://doi.org/10.1182/blood-2025-5567

Published: 2025

Journal Articles

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Blood (2024) 144 (Supplement 1): 731.

https://doi.org/10.1182/blood-2024-198614

Published: 2024

Journal Articles

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Blood (2024) 144 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2024-199110

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

Elias Jabbour, Gerhard Zugmaier, Pilar Martinez Sanchez, Jose J. Rifon, Vaibhav Agrawal, Ryan D Cassaday, Thomas Cluzeau, Françoise Huguet, Vladan Vucinic, Boris Böll, Anita W. Rijneveld, Mar Tormo, Maher Abdul-Hay, Paul R Gordon, Alessandro Rambaldi, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1440.

https://doi.org/10.1182/blood-2024-205662

Published: 2024

Journal Articles

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Blood (2024) 144 (15): 1570–1580.

https://doi.org/10.1182/blood.2023023754

Published: 2024

Includes: Supplemental data

Journal Articles

Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

Blood (2024) 144 (9): 988–1000.

https://doi.org/10.1182/blood.2023022154

Published: 2024

Includes: Supplemental data

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

Blood (2023) 142 (21): 1806–1817.

https://doi.org/10.1182/blood.2023021501

Published: 2023

Includes: Supplemental data

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Franck E. Nicolini, Elisabetta Abruzzese, Gabrielle Roth-Guepin, Rami Abi-Tayeh, Vincent Alcazer, Sandrine Hayette, Stéphane Morisset, Françoise Huguet, Miriam Iezza, Fausto Castagnetti, Delphine Rea

Blood (2023) 142 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2023-178326

Published: 2023

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study

Blood (2023) 142 (Supplement 1): 962.

https://doi.org/10.1182/blood-2023-177696

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only